Combination gene therapy targeting on interleukin-1β and RANKL for wear debris-induced aseptic loosening

Gene Therapy

Volumn 20, Issue 2, 2013, Pages 128-135

  Wang, H ^a,b   Jia, T H ^b   Zacharias, N ^c   Gong, W ^b   Du, H X ^b   Wooley, P H ^a,c   Yang, S Y ^a,c  

^a Orthopaedic Research Institute Incorporated   (United States)

^b SHANDONG UNIVERSITY   (China)

^c WICHITA STATE UNIVERSITY   (United States)

Author keywords

Osteoclastogenesis; Periprosthetic osteolysis; Synergetic effects

Indexed keywords

CATHEPSIN K; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN C FOS; STRESS ACTIVATED PROTEIN KINASE 1; TITANIUM; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE IMPLANT; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSDUCTION; IN VIVO GENE TRANSFER; INFLAMMATION; KNEE IMPLANT; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROSTHESIS LOOSENING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIBIA; VIRAL GENE THERAPY;

ANIMALS; BONE REGENERATION; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE, TUMOR; GENETIC THERAPY; IMPLANTS, EXPERIMENTAL; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; KNEE PROSTHESIS; MICE; MICE, INBRED BALB C; OSTEOCLASTS; OSTEOPROTEGERIN; PROSTHESIS FAILURE; RANK LIGAND; TITANIUM;

EID: 84873570949     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.1     Document Type: Article

References (34)

1. Keener JD, Callaghan JJ, Goetz DD, Pederson DR, Sullivan PM, Johnston RC. Twenty-five-year results after Charnley total hip arthroplasty in patients less than fifty years old: A concise follow-up of a previous report. J Bone Joint Surg Am 2003; 85-A: 1066-1072 (Pubitemid 36644789)
2. Maloney WJ, Smith RL. Periprosthetic osteolysis in total hip arthroplasty: The role of particulate wear debris. Instr Course Lect 1996; 45: 171-182
3. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342 (Pubitemid 40852708)
4. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001; 276: 20659-20672
5. Haynes DR, Crotti TN, Potter AE, Loric M, Atkins GJ, Howie DW et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg Br 2001; 83: 902-911 (Pubitemid 32785565)
6. Leibbrandt A, Penninger JM. RANK(L) as a key target for controlling bone loss. Adv Exp Med Biol 2009; 647: 130-145
7. Zhang T, Yu H, Gong W, Zhang L, Jia T, Wooley PH et al. The effect of osteoprotegerin gene modification on wear debris-induced osteolysis in a murine model of knee prosthesis failure. Biomaterials 2009; 30: 6102-6108
8. Yang SY, Mayton L, Wu B, Goater JJ, Schwarz EM, Wooley PH. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. Arthritis Rheum 2002; 46: 2514-2523
9. Zhang K, Jia TH, McQueen D, Gong WM, Markel DC, Wooley PH et al. Circulating blood monocytes traffic to and participate in the periprosthetic tissue inflammation. Inflamm Res 2009; 58: 837-844
10. Neale SD, Athanasou NA. Cytokine receptor profile of arthroplasty macrophages, foreign body giant cells and mature osteoclasts. Acta Orthop Scand 1999; 70: 452-458
11. Amstutz HC, Campbell P, Kossovsky N, Clarke IC. Mechanism and clinical significance of wear debris-induced osteolysis. Clin Orthop Relat Res 1992; 276: 7-18
12. Gowen M, Wood DD, Ihrie EJ, McGuire MK, Russell RG. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 1983; 306: 378-380 (Pubitemid 14242749)
13. Zhang L, Jia TH, Chong AC, Bai L, Yu H, Gong W et al. Cell-based osteoprotegerin therapy for debris-induced aseptic prosthetic loosening on a murine model. Gene Therapy 2010; 17: 1262-1269
14. Yang SY, Yu H, Gong W, Wu B, Mayton L, Costello R et al. Murine model of prosthesis failure for the long-term study of aseptic loosening. J Orthop Res 2007; 25: 603-611 (Pubitemid 46744725)
15. Chiba J, Rubash HE, Kim KJ, Iwaki Y. The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis. Clin Orthop Relat Res 1994; 300: 304-312 (Pubitemid 24085514)
16. Jacobs JJ, Roebuck KA, Archibeck M, Hallab NJ, Glant TT. Osteolysis: Basic science. Clin Orthop Relat Res 2001; 393: 71-77 (Pubitemid 33101699)
17. Takayanagi H. Inflammatory bone destruction and osteoimmunology. J Periodontal Res 2005; 40: 287-293 (Pubitemid 40977302)
18. Udagawa N, Takahashi N, Akatsu T, Tanaka H, Sasaki T, Nishihara T et al. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrowderived stromal cells. Proc Natl Acad Sci USA 1990; 87: 7260-7264
19. Kim N, Takami M, Rho J, Josien R, Choi Y. A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med 2002; 195: 201-209 (Pubitemid 34461264)
20. Yang S, Wu B, Mayton L, Evans CH, Robbins PD, Wooley PH. IL-1Ra and vIL-10 gene transfer using retroviral vectors ameliorates particle-associated inflammation in the murine air pouch model. Inflamm Res 2002; 51: 342-350 (Pubitemid 34743628)
21. Yang SY, Wu B, Mayton L, Mukherjee P, Robbins PD, Evans CH et al. Protective effects of IL-1Ra or vIL-10 gene transfer on a murine model of wear debrisinduced osteolysis. Gene Therapy 2004; 11: 483-491 (Pubitemid 38313169)
22. Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL et al. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 2002; 17: 192-199 (Pubitemid 34087651)
23. Ulrich-Vinther M, Carmody EE, Goater JJ, Sballe K, O'Keefe RJ, Schwarz EM. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg Am2002; 84-A: 1405- 1412 (Pubitemid 35407586)
24. Tsutsumi R, Hock C, Bechtold CD, Proulx ST, Bukata SV, Ito H et al. Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT. J Orthop Res 2008; 26: 1340-1346
25. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med (Berl) 2005; 83: 170-179 (Pubitemid 40487405)
26. Troen BR. The regulation of cathepsin K gene expression. Ann NY Acad Sci 2006; 1068: 165-172 (Pubitemid 43824146)
27. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997; 11: 3482-3496 (Pubitemid 28023969)
28. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA et al. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266: 443-448
29. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A et al. TRAF6
30. deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999; 13: 1015-1024
31. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999; 4: 353-362 (Pubitemid 29359450)
32. Gallo J, Raska M, Mrazek F, Petrek M. Bone remodeling, particle disease and individual susceptibility to periprosthetic osteolysis. Physiol Res 2008; 57: 339-349
33. Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D, Dougall WC. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 2002; 277: 44347-44356 (Pubitemid 36157870)
34. Yuan H, Gupte R, Zelkha S, Amar S. Receptor activator of nuclear factor kappa B ligand antagonists inhibit tissue inflammation and bone loss in experimental periodontitis. J Clin Periodontol 2011; 38: 1029-1036